Nucleotide Prodrugs as Treatment for Acute Myeloid Leukaemia (AML)

This project aims to improve outcomes for patients in Wales diagnosed with acute myeloid leukaemia (AML), a serious blood cancer with high incidence locally. Many patients in Wales face limited treatment options, particularly when standard therapy with Azacitidine stops working, leaving vulnerable groups, including older adults, at increased risk of poor survival. Developing new forms of Azacitidine that remain effective could directly benefit Welsh patients by increasing treatment success and reducing mortality.

This project develops next-generation Azacitidine prodrugs capable of treating Azacitidine-resistant AML. As the project focuses on Wales it allows testing and optimisation in the local population, ensuring clinical feasibility within existing Welsh NHS infrastructure. By reducing treatment inequalities and increasing survival rates for Welsh AML patients, the project aligns with CRW priorities and strengthens Wales-led translational cancer research.

For patients in Wales, this research has the potential to provide more effective AML treatments, improve survival, and reduce disparities in cancer outcomes. In the longer term, it supports Wales-led innovation in cancer therapeutics and ensures local patients benefit early from cutting-edge research.